Abstracts tagged "prognostic factors"

Abstract Number: 1775 • ACR Convergence 2021
Isolated Axial versus Concomitant Peripheral Disease in Psoriatic Arthritis
Timothy Kwok¹, Mitchell Sutton², Richard Cook³, Daniel Pereira⁴ and Dafna Gladman⁵, ¹Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Department of Statistics and Actuarial Sciences, University of Waterloo, Waterloo, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Isolated axial involvement exists in 2 to 5% of all psoriatic arthritis (PsA) patients. However, it is currently unknown whether patients with isolated axial…
Abstract Number: 0083 • ACR Convergence 2021
Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome
Tali Eviatar¹, Stanley Niznik², Nancy Agmon-Levin² and Daphna Paran³, ¹Tel Aviv Sourasky Medical Center, Givataim, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel
Background/Purpose: Cardiac valve involvement in the APS is prevalent, necessitating valve surgery in about 5% of the patients. Data regarding valve surgery outcomes in APS…
Abstract Number: 1834 • ACR Convergence 2021
To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a Bio-naïve Patient Population
Marijn Vis¹, Pascal Richette², Ramirez Julio³, Marlies Neuhold⁴, Robert Wapenaar⁵, Elke Theander⁶, Wim Noel⁷, May Shawi⁸, Alexa Kollmeier⁹ and William Tillett¹⁰, ¹Erasmus MC, Badhoevedorp, Netherlands, ²Lariboisiere Hospital, Paris, France, ³Hospital Universitari Clinic, Barcelona, Spain, ⁴Janssen-Cilag, Zug, Switzerland, ⁵Janssen-Cilag BV, Breda, Netherlands, ⁶Janssen Cilag, Lund, Sweden, ⁷Janssen Pharmaceutica, Vilvoorde, Belgium, ⁸Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁹Janssen Research & Development, LLC, La Jolla, CA, ¹⁰Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19-subunit, has demonstrated efficacy across joint and skin endpoints at Week 24 (W24) in the Phase…
Abstract Number: 0254 • ACR Convergence 2021
Patient and Disease-Level Factors Associated with Sustained Cessation of Medication for Disease Remission in Systemic Juvenile Idiopathic Arthritis
Elaine Flanagan¹, Rosemary Peterson², Susan Shenoi³, Helena Chang⁴, Kelly Wang⁴, Rebecca Trachtman⁴ and Karen Onel⁵, ¹Emory/CHOA, Atlanta, GA, ²Dell Children's Medical Center, Austin, TX, ³Seattle Children's Hospital, Seattle, WA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: The emergence of IL-1 and IL-6 inhibitors (biologics) for the treatment of systemic juvenile idiopathic arthritis (SJIA) has dramatically improved patient outcomes. With higher…
Abstract Number: 1848 • ACR Convergence 2021
Untangling the Gut: A Phenome-Wide Association Study of Drugs and Diseases with Gastrointestinal Dysfunction in Systemic Sclerosis
Rory Maclean¹, Fiza Ahmed², Voon Ong³, Charles Murray⁴ and Christopher Denton⁵, ¹Royal Free Hospital & University College London, London, United Kingdom, ²Royal Free Hospital, Ilford, United Kingdom, ³University College London Medical School Royal Free Campus, London, United Kingdom, ⁴Royal Free Hospital, London, United Kingdom, ⁵University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Gastrointestinal dysfunction (SSc-GI) is a significant burden to patients with systemic sclerosis (SSc), particularly in those with longstanding disease. The management of SSc-GI is…
Abstract Number: 0344 • ACR Convergence 2021
Anti-gAChR Antibody as a Novel Biomarker for Lupus Enteritis in Systemic Lupus Erythematosus
Kuniyuki Aso¹, Michihito Kono¹, Keita Ninagawa¹, Nobuya Abe¹, Yuichiro Fujieda¹, Masaru Kato¹, Olga Amengual¹, Kenji Oku¹ and Tatsuya Atsumi², ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Hokkaido University, Sapporo, Japan
Background/Purpose: Anti-ganglionic nicotinic acetylcholine receptor (gAChR) antibody (Ab) is associated with widespread autonomic dysfunction in autoimmune autonomic ganglionopathy. Although it is also detected in several…
Abstract Number: 0388 • ACR Convergence 2021
Prediction Tool for Damage Accrual Trajectory in Incident Systemic Sclerosis
Ariane Barbacki¹, Ada Man², Mianbo Wang³, Dylan Johnson⁴, Yuqing Zhang⁵, Mandana Nikpour⁶ and Murray Baron⁷, ¹McGill University, Montral, Montréal, QC, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Lady Davis institute for Medical Research, Montréal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Massachusetts General Hospital, Quincy, MA, ⁶University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁷Jewish General Hospital, Montréal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease associated with the accrual of organ damage over time, which can be measured using the Scleroderma…
Abstract Number: 0455 • ACR Convergence 2020
HLA-B27 and Host Immune Response: Lessons from Reactive Arthritis
Sophie Wojcik¹, Davina Morris², Gillian Fitzgerald³, Steve Ramkissoon⁴, Nigil Haroon² and Robert Inman⁵, ¹UHN, Montreal, QC, Canada, ²University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, ⁴UHN, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada
Background/Purpose: The natural history of reactive arthritis (ReA) remains poorly understood. Certain patients with ReA will go on to develop a chronic course while others…
Abstract Number: 1718 • ACR Convergence 2020
Impact of Treatments on Radiographic Progression over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort
Joanna Kedra¹, David Hajage¹, Alexandre Lafourcade¹, Bernard Combe², Maxime Dougados³ and Bruno Fautrel⁴, ¹Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR S1136, Paris, France, Paris, France, ²University of Montpellier, Montpellier, France, ³Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, ⁴Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France
Background/Purpose: Long-term observational studies on the prediction of structural damage progression (SDP) in rheumatoid arthritis (RA) have mostly considered patients baseline characteristics and have rarely…
Abstract Number: 0480 • ACR Convergence 2020
Impact of Targeting Remission or Low Disease Activity on 10-year Severity in Rheumatoid Arthritis : Data from ESPOIR Cohort
Julia Dupont¹, Gregory Guernec², Yannick Degboé³, Frédéric Lioté⁴, Olivier Vittecoq⁵, Arnaud Constantin⁶ and Adeline Ruyssen Witrand⁷, ¹University Hospital of Thoulouse, Toulouse, ²Inserm UMR 1027, TOULOUSE CEDEX 9, France, ³University Hospital of Toulouse, Toulouse, ⁴AP-HP, Paris, France, ⁵University Hospital of Rouen, Rouen, France, ⁶Rheumatology Department, Toulouse University Hospital, Toulouse, France, ⁷Rheumatology center, University Hospital of Toulouse, Inserm 1027, University Paul Sabatier, Toulouse, France, Toulouse, France
Background/Purpose: The aim of rheumatoid arthritis (RA) treatment is to target remission or at least low disease activity (LDA). We previously showed that SDAI remission…
Abstract Number: 1749 • ACR Convergence 2020
Efficacy of Filgotinib in Patients with Rheumatoid Arthritis with Poor Prognostic Factors: Post Hoc Analysis
Daniel Aletaha¹, Rene Westhovens², Cecile Gaujoux-Viala³, Giovanni Adami⁴, Alan Matsumoto⁵, Paul Bird⁶, Osvaldo Daniel Messina⁷, Maya Buch⁸, Beatrix Bartok⁹, Zhaoyu Yin⁹, Ying Guo¹⁰, Thijs Hendrikx¹¹ and Gerd Burmester¹², ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ²University Hospitals Leuven, Belgium, Leuven, Belgium, ³Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, EA2415, University of Montpellier, Montpellier, France, Nîmes, France, ⁴University of Verona, Verona, Italy, ⁵Arthritis and Rheumatism Assoc, Wheaton, MD, ⁶University New South Wales, Sydney, Australia, ⁷IRO Medical Ctr & Cosme Argerich Hospital, Buenos Aires, Argentina, ⁸Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ⁹Gilead Sciences, Inc., Foster City, CA, ¹⁰Gilead Sciences, Inc., Foster City, ¹¹Galapagos BV, Leiden, Netherlands, ¹²Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) with poor prognostic factors (PPF) are at risk for RA progression if disease activity is not rapidly controlled.…
Abstract Number: 0490 • ACR Convergence 2020
Fine Specificity Anti-Citrullinated Protein Antibodies as Biomarkers for Prediction of Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease
Vanessa Kronzer¹, Weixing Huang², Paul Dellaripa³, Sicong Huang⁴, Vivi Feathers², Bing Lu⁵, Christine Iannaccone⁴, Ritu Gill⁶, Hiroto Hatabu⁷, Mizuki Nishino⁷, Cynthia Crowson⁸, John Davis¹, William Robinson⁹, Tripta Rughwani⁹, Jeremy Sokolove¹⁰, Michael Weinblatt⁴, Nancy Shadick¹¹, Tracy J. Doyle¹² and Jeffrey Sparks¹¹, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁶Beth Israel Deaconess Medical Center, Boston, MA, ⁷Department of Radiology; Brigham and Women’s Hospital, Boston, ⁸Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ⁹Stanford University, Palo Alto, CA, ¹⁰Stanford University, Mountain View, CA, ¹¹Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹²Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: Seropositivity for anti-citrullinated protein antibodies (ACPA) has been shown to increase risk for RA-associated interstitial lung disease (RA-ILD). However, RA-related autoantibodies used in clinical…
Abstract Number: 1763 • ACR Convergence 2020
Blending Hierarchical Cluster Analysis and Cluster-Specific Regressions to Predict Clinical Outcome to Tofacitinib Treatment in Patients with Rheumatoid Arthritis
Robert Landewé¹, Daniel H Solomon², Gianluca Bonfanti³, Luigi Manca³, John C Woolcott⁴, Jasper Deuring⁵, Stephen Watt⁶, Pritha Bhadra Brown⁶, Rebecca Germino⁶, Birol Emir⁶ and Roger A Edwards⁷, ¹Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ²Brigham and Women's Hospital, Boston, MA, ³Fair Dynamics Consulting, SRL, Milan, Italy, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Rotterdam, Netherlands, ⁶Pfizer Inc, New York, NY, ⁷Health Services Consulting Corporation, Boxborough, MA
Background/Purpose: Patients with RA exhibit wide variations in response to therapy. Early treatment response profiles may help us to better predict subsequent treatment response, thus…
Abstract Number: 0637 • ACR Convergence 2020
Clinical and Treatment Features of Rheumatoid Arthritis in HIV-Infected Individuals Followed Longitudinally over Time
Benjamin Naovarat¹, Francis Williams¹ and John Reveille², ¹The University of Texas McGovern Medical School, Houston, TX, ²Department of Internal Medicine, University of Texas, Houston, TX
Background/Purpose: With the successful treatment of HIV-1 infection with combination anti-retroviral treatment, immune-mediated diseases that were rarely encountered in HIV positive individuals in the pre-treatment…
Abstract Number: 1803 • ACR Convergence 2020
Ability of Innate, Adaptive, and TNF-Superfamily Immune Pathways to Characterize Disease Activity and Inform a Refined Lupus Disease Activity Immune in a Confirmatory Cohort of SLE Patients
Melissa Munroe¹, Wade DeJager², Susan Macwana², Ly Tran², Joel Guthridge², Eldon Jupe³, Daniele DeFreese³, Ryan Newhardt³, Mohan Purushothaman³, Sanjiv Sharma³, Nancy Redinger², Teresa Aberle², Stan Kamp², Cristina Arriens², Eliza Chakravarty², Joan Merrill⁴ and Judith James⁵, ¹Oklahoma Medical Research Foundation/Progentec Diagnostics, Inc., Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Progentec Diagnostics, Inc., Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease driven by complex immune dysregulation, involving altered immune mediators and accumulation of autoantibody (AutoAb) specificities.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].